Magenta therapeutics anticipates that its cash, cash equivalents will be sufficient to fund operations and capital expenditures into q4 of 2021

Magenta therapeutics reports fourth quarter and full year 2019 financial results and recent business highlights.magenta therapeutics - anticipates that its cash, cash equivalents will be sufficient to fund operations and capital expenditures into q4 of 2021.magenta therapeutics inc - advancing mgta-117 to generate clinical data in 2021.
DNTH Ratings Summary
DNTH Quant Ranking